Financing channel feed

Metaphore Biotech­nolo­gies seeks to mim­ic na­ture with $50M for au­toim­mune, im­munol­o­gy drugs out of Flag­ship

Last year
Startups

UniQure sells part of Hem­genix roy­al­ty for $400M cash

Last year
Deals

Bel­gian biotech Du­a­lyx en­ters Treg field with $44M for 2024 clin­i­cal en­try

Last year
Startups

From 5AM's nest, neu­ro­science start­up Nido Bio­sciences launch­es with $109M and PhI un­der­way

Last year
Startups

GSK rais­es $1B+ from sell­ing shares in con­sumer health spin­off Ha­le­on

Last year

New blood and cell ther­a­py-fo­cused ven­ture fund emerges with $50M and a Jen­nifer Doud­na spin­out in tow

Last year
Startups
Cell/Gene Tx

Botox com­peti­tor Daxxi­fy hits $15.4M in Q1 earn­ings as mak­er faces trade se­crets law­suit

2 years ago
Law

French biotech jumps in­to type 1 di­a­betes space with $30M Se­ries A round

3 years ago
Startups

Q&A: Ace­lyrin CEO Shao-Lee Lin de­tails biotech's $540M IPO, find­ing 'di­a­monds in the rough'

3 years ago
Startups

Ace­lyrin's IPO is an 'N of 1', in­dus­try in­sid­ers say, as 50+ biotechs are still wait­ing for their mo­ment on the mar­kets

3 years ago
Startups

Im­muno­Gen prices $325M pub­lic of­fer­ing af­ter con­fir­ma­to­ry tri­al in ovar­i­an can­cer

3 years ago

Re­verse merg­ers say hey as biotechs trade low, hunt for al­ter­na­tives and launch few IPOs

3 years ago
Startups
Deals

Cowen, Long­wood add $735M to bio­phar­ma's pool of mon­ey

3 years ago
Startups

Ra­dioan­ti­body start­up led by prostate can­cer ex­perts rais­es $90M

3 years ago

Mor­phic Ther­a­peu­tic fol­lows pos­i­tive da­ta read­out for UC drug with $240M pub­lic of­fer­ing

3 years ago

ARTHEx nabs Se­ries B for clin­i­cal tri­al of ASO in my­oton­ic dy­s­tro­phy as Ver­tex’s deals heat up the space

3 years ago
Startups

Durham start­up rais­es Se­ries A to tack­le un­drug­gable pro­teins, in­clud­ing can­cer bad­die Myc, with gen­er­a­tive AI

3 years ago
Startups
AI

Mile­stone Mon­day for Im­mat­ics’ Bris­tol My­ers-al­lied cell ther­a­py and 2sev­en­ty bio’s No­vo-part­nered he­mo­phil­ia A work

3 years ago
Pharma
Cell/Gene Tx

'Un­drug­gable is on­ly at a giv­en point in time': Promi­nent Cal­i­for­nia sci­en­tists launch Ini­tial Ther­a­peu­tics with $75M

3 years ago
Startups

Ace­lyrin sets out for a 2021-sized IPO for Cal­i­for­nia biotech’s PhI­II drug

3 years ago
People
Startups

One SPAC inks biotech merg­er, while an­oth­er linked to for­mer Biden can­cer moon­shot leader will shut down

3 years ago
Deals

Fore­sight Di­ag­nos­tic­s' ap­proach for the ear­li­er de­tec­tion of can­cer re­cur­rence pulls in near­ly $59M

3 years ago

Pat­tern Bio­science rais­es $28.7M Se­ries C for faster, more ef­fi­cient an­tibi­ot­ic re­sis­tance test

3 years ago
Diagnostics

‘Sleep­ing block­buster’: MPM leads $53M Se­ries E for An­ti­va as biotech seeks sec­ond go at tack­ling HPV 

3 years ago
First page Previous page 33343536373839 Next page Last page
A service from the Financial Times